| Outcome Measures: |
Primary: Change From Baseline in Participant Hemoglobin A1C Level at Week 24, A1C is measured as a percent. A1C is the key glycemic parameter which correlates with reduction of risk of diabetic complications., Baseline and Week 24|Percentage of Participants With Confirmed Anti-Insulin Antibodies (AIA) up to Week 24, Percentage of participants is a cumulative percentage of participants with any confirmed AIA (including baseline) up to Week 24., Up to 24 weeks | Secondary: Change From Baseline in Participant Body Weight at Week 24, Change from baseline in participant body weight at Week 24., Baseline and Week 24|Percentage of Participants Experiencing an Adverse Event (AE) of Hypoglycemia Up to Week 24, Symptomatic events assessed as likely to be hypoglycemia were to be reported by investigators as adverse events of hypoglycemia; a concurrent glucose measurement was not required. Asymptomatic events with confirmed glucose levels \</= 70mg/dL (\</= 3.9mmol/L) could also be reported as adverse events at the discretion of the investigator., Up to 24 weeks|Percentage of Participants Experiencing an AE Over the 24-week Treatment Period, An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the investigational product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the investigational product, is also an AE., Up to 24 weeks|Daily Basal Insulin Dose (Units) at Week 24, The daily basal insulin dose (measured in units) for any given visit is defined as the average dose from the three most recent days preceding the visit date., Week 24|Daily Basal Insulin Dose Per Body Weight (Units/kg) at Week 24, Basal insulin dose per body weight was calculated as total insulin dose (units) per day divided by body weight in kilograms (kg)., Week 24|Change From Baseline in Participant Fasting Plasma Glucose (FPG) at Week 24, Participants fasted (no food or drink except water and non-antihyperglycemic non-study medications as prescribed) for at least 8 hours prior to all study visits., Baseline and Week 24|Change From Baseline in Participant 7-Point Average of Self-Monitored Blood Glucose (SMBG) at Week 24, 7-Point Average of SMBG was defined as the mean of blood glucose measurements taken at the following 7 times: before morning meal, after morning meal, before midday meal, after midday meal, before evening meal, after evening meal or at bedtime, and between 2 AM and 4 AM., Baseline and Week 24|Percentage of Participants With Hemoglobin A1C <7% at Week 24, Percentage of participants with A1C \<7.0% (53 mmol/mol) at Week 24., Week 24|Percentage of Participants With Hemoglobin A1C <6.5% at Week 24, Percentage of participants with A1C \<6.5% (48 mmol/mol) at Week 24., Week 24
|
